- Home
- SANG vs MRSN Comparison
SANG vs MRSN Comparison
Compare SANG & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SANG
- MRSN
- Stock Information
- Founded
- SANG 1984
- MRSN 2001
- Country
- SANG Canada
- MRSN United States
- Employees
- SANG 671
- MRSN N/A
- Industry
- SANG Computer Software: Programming Data Processing
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- SANG Technology
- MRSN Health Care
- Exchange
- SANG Nasdaq
- MRSN Nasdaq
- Market Cap
- SANG 247.2M
- MRSN 252.0M
- IPO Year
- SANG 2021
- MRSN 2017
- Fundamental
- Price
- SANG $7.37
- MRSN $0.62
- Analyst Decision
- SANG
- MRSN Buy
- Analyst Count
- SANG 0
- MRSN 6
- Target Price
- SANG N/A
- MRSN $6.00
- AVG Volume (30 Days)
- SANG 9.1K
- MRSN 7.3M
- Earning Date
- SANG 02-06-2025
- MRSN 02-26-2025
- Dividend Yield
- SANG N/A
- MRSN N/A
- EPS Growth
- SANG N/A
- MRSN N/A
- EPS
- SANG N/A
- MRSN N/A
- Revenue
- SANG $244,406,000.00
- MRSN $34,837,000.00
- Revenue This Year
- SANG $3.36
- MRSN N/A
- Revenue Next Year
- SANG $7.39
- MRSN N/A
- P/E Ratio
- SANG N/A
- MRSN N/A
- Revenue Growth
- SANG N/A
- MRSN N/A
- 52 Week Low
- SANG $2.50
- MRSN $0.56
- 52 Week High
- SANG $7.65
- MRSN $6.28
- Technical
- Relative Strength Index (RSI)
- SANG 66.04
- MRSN 20.37
- Support Level
- SANG $6.97
- MRSN $0.56
- Resistance Level
- SANG $7.65
- MRSN $1.45
- Average True Range (ATR)
- SANG 0.24
- MRSN 0.14
- MACD
- SANG 0.01
- MRSN -0.06
- Stochastic Oscillator
- SANG 66.90
- MRSN 6.49
About SANG Sangoma Technologies Corporation
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.